Skip to content

An Examination of Cholinergic Symptoms Produced by the Fly Agaric Mushroom Amanita muscaria (Agaricomycetes): Revisiting the Role of Muscarine.

Kevin Feeney, James Kababick, Stacy Wise

International journal of medicinal mushrooms January 1, 2025 DOI: 10.1615/intjmedmushrooms.2025058603 via PubMed

Summary

AI-generated from the abstract

Decades of consensus held that the mushroom Amanita muscaria contains negligible amounts of the toxic compound muscarine, based on a 1950s study reporting 0.0003% concentration. This view persisted despite frequent reports of cholinergic symptoms (e.g., salivation, sweating, nausea) in people who consumed the mushroom. To resolve the discrepancy, researchers surveyed 53 individuals who experienced such symptoms after eating A. muscaria, analyzed mushroom samples from three participants and independently collected specimens using HPLC-MS/MS, and compiled commercial analyses. Muscarine concentrations ranged from 0.004% to 0.043%, far exceeding the historical value. The findings indicate that muscarine levels in A. muscaria vary widely and can reach physiologically significant amounts, contradicting the long-held assumption of insignificance.

Study at a glance

Characteristics Mixed methods: survey and laboratory analysis Peer reviewed
Sample size 53
Population Individuals who experienced cholinergic symptoms following ingestion of Amanita muscaria
Citations 1
Key finding Muscarine concentrations in Amanita muscaria range from 0.004% to 0.043%, substantially higher than the previously accepted 0.0003%, indicating that the compound can reach physiologically significant levels.

Abstract

The English mycological and toxicological literature has, for decades, asserted that muscarine concentrations in Amanita muscaria are insignificant based on a study from the 1950s that demonstrated muscarine levels in fresh A. muscaria mushrooms at a meager 0.0003%. This position has been maintained despite frequent reports of cholinergic symptoms following consumption of this mushroom and despite the dated study upon which this position is based. To update the literature on A. muscaria's pharmacology and to address disparities between the current scientific consensus on the role of muscarine, a cholinergic compound, in A. muscaria poisonings and the frequent reports of cholinergic symptoms following its ingestion, four steps were taken: (1) surveys were collected from 53 individuals who experienced cholinergic symptoms following ingestion of A. muscaria; (2) mushroom samples were procured for HPLC-MS/MS analysis from three survey participants; (3) mushrooms were collected independently for HPLC-MS/MS analysis; and (4) commercial analyses of Amanita muscaria were compiled to illustrate a range of muscarine concentrations. Survey results demonstrated that mild-to-moderate cholinergic symptoms were experienced at doses that reflect common use of the mushroom for recreational, therapeutic, and spiritual purposes (1-20 g dried). Results of HPLC-MS/MS analyses demonstrated muscarine concentrations ranging from 0.004% up to 0.043%, significantly exceeding the consensus value. Study findings demonstrate that current understandings of muscarine concentrations in A. muscaria are inaccurate, and that the occurrence of muscarine in A. muscaria must be understood as a broad range, one that ranges from the insignificant up to physiologically significant levels.

Comments

No comments yet.

Log in to comment